Perrigo Company plc Ordinary Shares (NYSE:PRGO)
On Friday, Perrigo Company plc Ordinary Shares (NYSE:PRGO)’s shares declined -6.16% to $146.90.
PRGO has the market capitalization of $21.51 billion. The stock has P/B ratio of 2.00 while EPS was $0.97. Institutional ownership of the company was 82.9% while 146.40 million shares were outstanding. Net profit margin of the Company was 4.80% while its gross profit margin was 38.80%. Share of the company moved below its SMA 50 with -10.81%. ROE ratio was 2.40% while ROI was 3.90%.
The mean estimate for the short term price target for Perrigo Company plc Ordinary Shares (NYSE:PRGO) stands at $199.78 according to 9 Analysts. The higher price target estimate for the stock has been calculated at $230.00 while the lower price target estimate is at $156.00.
Analysts mean recommendation for the stock is 2.40. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Perrigo Company plc, through its subsidiaries, develops, manufactures, and markets over-the-counter (OTC) consumer goods and pharmaceutical products worldwide. The company operates through Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals (Rx Pharmaceuticals), Specialty Sciences, and Other segments.
Merck & Co., Inc. (NYSE:MRK)
Merck & Co., Inc. (NYSE:MRK)’s shares dropped -2.02% to $53.03.
MRK has market capitalization of $148.14 billion. Its current ratio was 1.60 while its shares were above its 50 days simple moving average with 1.93%. The company offered earning per share of $3.75 while its 2.79 million shares were outstanding. YTD performance of the company was -6.62%. Stock volatility for the week was 1.62% while for the month it was shown at 1.88%.
The mean estimate for the short term price target for Merck & Co., Inc. (NYSE:MRK) stands at $62.41 according to 17 Analysts. The higher price target estimate for the stock has been calculated at $72.00 while the lower price target estimate is at $53.00.
Analysts mean recommendation for the stock is 2.40. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures.
Edgewell Personal Care Co (NYSE:EPC)
At the end of Friday’s trade, Edgewell Personal Care Co (NYSE:EPC)‘s shares dipped -6.88% to $73.07.
EPC Its past 5-day performance at -11.23%. So far in 2015, the company has a year-to-date performance of -43.16%. The stock, as of last close, traded -3.26% up from its 52 week low and was -31.72% below its 52 week high. Its latest closing price was -23.19% below the SMA200 while the distance from SMA 50 and SMA 20 was -12.58% and -13.02% respectively.
The mean estimate for the short term price target for Edgewell Personal Care Co (NYSE:EPC) stands at $100.10 according to 10 Analysts. The higher price target estimate for the stock has been calculated at $118.00 while the lower price target estimate is at $90.00.
Analysts mean recommendation for the stock is 2.50. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Edgewell Personal Care Company, formerly Energizer Holdings, Inc., is engaged in providing personal care products. The Company offers its products in various categories, including shaving, sun care, feminine care, infant care, skin care and pet care.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.